BSE filing, NSE: GVBL. Summary written from the filing by ALFA Finder's alert engine.
Genomic Valley Biotech Ltd: key numbers
- Share price
- ₹43.63
- Market cap
- ₹13.33 Cr
- Revenue (annual)
- ₹0.27 Cr
- Net profit (annual)
- ₹0.03 Cr
- P/E (TTM)
- 655.2×Sector 46.1×
- Promoter holding
- 46.06%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genomic Valley Biotech Ltd
All →Genomic Valley Biotech Open Offer: ₹57.97 Cr
Manager to the Open Offer filed GVB's DPS announcing an open offer for up to 7,94,170 shares at ₹730. The Acquirers seek about 21% of the company.
- Value
- ₹57.97 Cr
Genomic Valley Biotech Board Meeting Date
Board meeting scheduled for October 30, 2026, to consider unaudited Q2 and H1 FY27 financial results. Trading window closed pending results publication.
Genomic Valley Biotech Open Offer: ₹2.38 Cr
Acquirers Pankaj Grover and Abhisek Gupta announced an open offer for 7.94 lakh shares of Genomic Valley Biotech Ltd at ₹30 per share.
- Value
- ₹2.38 Cr
Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This mandatory disclosure provides details on the company's shareholding structure.
Genomic Valley Biotech Other Announcement
Genomic Valley Biotech Limited received approval from the Registrar of Companies to extend the AGM deadline for FY26 to 31st December 2026. This is a regulatory compliance update.
Genomic Valley Biotech Q1 FY27 Results: Net Profit ₹146,162 Cr, Down 40.7% YoY
Genomic Valley Biotech Ltd reported revenue from operations of ₹380,000 Cr (-57.8% YoY) and net profit of ₹146,162 Cr (-40.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹146,162 Cr · -40.7% YoY
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr